Senti Biosciences Holdings, Inc.
SNTI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001854270
No open-market purchases or sales by Senti Biosciences Holdings, Inc. insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $6.37M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Senti Biosciences Holdings, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Senti Biosciences Holdings, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | 74,843 | Mar 11, 2026 | 2 |
| Lu Timothy K | CEO | 639,583 | Mar 11, 2026 | 2 |
| Baum Bryan Daniel | Director | – | Jul 21, 2025 | 0 |
| Mathers Edward T | Director | – | Jun 27, 2025 | 0 |
| Collins James J. | Director | – | Jun 27, 2025 | 0 |
| Tang Donald F | Director | – | Jun 27, 2025 | 0 |
| Cooperstone Brenda | Director | – | Jun 27, 2025 | 0 |
| Schulz Fran | Director | – | Jun 27, 2025 | 0 |
| Hsiung Feng | Director | – | Jun 27, 2025 | 0 |
| Celadon Partners SPV 24 | 10% Owner | 9,777,000 | Mar 14, 2025 | 0 |
| Sandell Scott D | 10% Owner | 3,775,615 | Mar 12, 2025 | 0 |
| Baskett Forest | 10% Owner | 3,775,615 | Mar 12, 2025 | 0 |
| Florence Anthony A. Jr. | 10% Owner | 3,775,615 | Mar 12, 2025 | 0 |
| New Enterprise Associates 15, L.P. | 10% Owner | 3,775,615 | Mar 12, 2025 | 0 |
| Makhzoumi Mohamad | 10% Owner | 3,775,615 | Mar 12, 2025 | 0 |
| NEA Partners 15, L.P. | 10% Owner | 3,775,615 | Mar 12, 2025 | 0 |
| Nea 15 GP, LLC | 10% Owner | 3,775,615 | Mar 12, 2025 | 0 |
| Bayer Aktiengesellschaft | 10% Owner | 2,809,848 | Mar 12, 2025 | 0 |
| Bayer Healthcare LLC | 10% Owner | 2,809,848 | Mar 12, 2025 | 0 |
| Bayer World Investments B.V. | 10% Owner | 2,809,848 | Mar 12, 2025 | 0 |
| Bayer US Holding LP | 10% Owner | 2,809,848 | Mar 12, 2025 | 0 |
| Cross John Harry III | Chief Financial Officer | – | Mar 11, 2025 | 0 |
| Farokhzad Omid | Director | – | Jul 12, 2024 | 0 |
| Knobelman Deborah | Chief Financial Officer | 131,000 | Feb 2, 2024 | 0 |
| Berland Susan D | Director | – | Jun 21, 2023 | 0 |
| Lee Philip J | Chief Technology Officer | – | Feb 2, 2023 | 0 |
| Epstein David R | Director | 123,252 | Jul 15, 2022 | 0 |
| Dynamics Sponsor LLC | Director, 10% Owner | 0 | Jun 10, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 6, 2025 (view filing) | Feb 4-6 | 2 days | Lu Timothy KCEO | SSale | −4.47K | $4.11 | −$18.3K | −5.2%82.1K after | 2 lots |
| Feb 6, 2025 (view filing) | Feb 4-6 | 2 days | Rajangam KanyaPres. & Chief Med. & Dev. Off. | SSale | −1.48K | $4.11 | −$6.07K | −14.6%8.62K after | 2 lots |
| Dec 11, 2024 (view filing)7:38 PM ET | Dec 9 | 2 days | Bayer Aktiengesellschaft and 3 others10% Owner | PPurchase | +5.55M | – | – | –3.33M after | Derivative2 lots |